Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulations

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 2, 2002, Pages 169-175

  Konsil, Julraht ^a   Mason Jr , David H ^a   Stevens, Ruth E ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MICHAELIS MENTEN KINETICS; NORMAL HUMAN; OSMOTIC PUMP; RANDOMIZED CONTROLLED TRIAL; SIMULATION; TABLET FORMULATION; TIME; VOLUNTEER;

ADULT; ANTIMANIC AGENTS; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 0036587612     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. McNamara, JO., Drugs Effective in the Therapy of the Epilepsies, in Hardman, JG, Limbird, LE., Molinoff, PB., Ruddon, RW., Gilman, AG. (eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., McGraw-Hill, INC, New York, NY, pp 473-475, 1996.
2. Levy, RH., Wilensky, AJ., Anderson, GD., Carbamazepine, Valproic Acid, Phenobarbital, and Ethosuximide. In Evans, WE., Schentag, JJ., Jusko, WJ. (Eds), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd ed. Applied Therapeutics, Spokane WA, pp 26-1 to 26-29, 1992.
3. Kudriakova TB., Sirota LA., Rozova GI., Gorkov VA., Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol, 33:611-615, 1992.
4. Tomson T., Tybring G., Bertilsson L., Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther, 33:58-65,1983.
5. Eichelbaum, M., Ekbom, K., Bertilsson, L., Ringberger, VA. and Rane, A., Plasma kinetics of carbamazepine and its epoxide metabolites in man after single and multiple doses. Eur J Clin Pharmacol, 8:337-341, 1975.
6. Faigle, JW., Feldmann, KF., Carbamazepine biotransformation, in Levy, R., Mattson, R., Meldrum, B., Penry, JK., Dreifuss, FE. (eds) Antiepileptic drugs, 3rd ed., Raven Press, New York, NY, pp 491-504,1989.
7. Bertilsson, L., Tomson, T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet, 11:177-198, 1986.
8. Albright, PS., Bruni, J. Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats. Neurology, 34:1383-1386, 1984.
9. Bourgeois, BFD., Wad, N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10, 11-epoxide in mice. J Pharmacol Exp Ther 231:411-415, 1984.
10. Hoppener, RJ., Kvyer, A., Meijer, JWA., Hulsman, J. Correlation between daily fluctuation of carbamazepine serum levels and intermittent side-effects. Epilepsia, 21:341-350, 1980.
11. Riva, R., Albani, F., Ambrosetto, G., Contin, M., Cortelli, P., Perucca, E., Baruzzi, A. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia, 25:4776-4781, 1984.
12. Fichsel, H. and Fuchs, V. Twenty-four hour serum concentration profiles in epileptic children of a new carbamazepine retard preparation. Epilepsia, 29:342, 1988.
13. Aldenkamp, AP., Alpherts, WCJ., Moerland, MC., Otter-vanger, N., Van Parys, JAP. Controlled-release carbamazepine: cognitive side-effects in patients with epilepsy. Epilepsia, 28:507-514, 1987.
14. Remy, C. Comparative open trial of carbamazepine and slow-release carbamazepine in epilepsy in adults. Presse Med, Mar 24;19(11):511-513,1990.
15. Dhalla, Z., Bruni, J., Sutton, J. A comparison of efficacy and tolerability of controlled release carbamazepine with conventional carbamazepine. Can J Neural Sci, 18: 66-68, 1991.
16. McKee, PJW., Blacklaw, J., Butler, E., Gilham, RA., Brodie, MJ. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. Br J Clin Pharmacol, 32: 99-104, 1991.
17. Stevens, RE,, Limsakun, T., Evans, G., Mason, JH.3rd. Controlled, Multidose, Pharmacokinetic Evaluation of Two Extended-Release Carbamazepine Formulation (Carbatrol and Tegretol-XR). J Pharm Sci, 87:1531-1534, 1998.
18. Hooper, WD., King, AR., Patterson, M., Dickinson, RG., Eadie, MJ. Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. Ther Drug Monit, 7(1):36-40, 1985.
19. Spina, E., Tomson, T., Svensson, JO., Faigle, JW., Bertilsson, L. Single-dose kinetics of enteric-coated formulation of carbamazepine-10, 11-epoxide, an active metabolite of carbamazepine. Ther Drug Monit, 10: 382-385, 1988.
20. Bonneton, J., Iliadis, A., Genton, P., Dravet, C., Viallat, D., Mesdjian, E. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy. Epilepsy Research, 14:257-263, 1993.
21. Chang, SL. and Levy, RH. Inhibition of epoxidation of carbamazepine by valproic acid in the isolated perfused rat liver. J Pharmacokinet Biopharm 13:453-466, 1985.
22. Sumi, M., Watari, N., Umezawa, O., Kaneniwa, N. Pharmacokinetic Study of Carbamazepine and Its Epoxide Metabolite in Humans. J Pharmacobio-Dyn, 10:652-661, 1987.
23. ADAPT II release 4.0 "Copyright 1997 Biomedical Simulations Resource, University of Southern California, California, USA.
24. Hvidberg, EF. and Dam, M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1: 161-188, 1976.
25. Martin ES 3d, Crismon ML, Godley PJ Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy 11: 296-302,1991.
26. Hooper, WD., King, AR., Patterson, M., Dickinson, RG., Eadie, MJ. Simultaneous plasma carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. Ther Drug Monit, 7:36-40, 1985.
27. Bernus, I., Dickinson, RG., Hooper, WD., Eadie, MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 47: 355-360, 1994.
28. Bertilsson, L., Hojer, B., Tybring, G., Osterloh, J., Rane, A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther, Jan;27(1):83-88,1980.
29. Riad, LE., Chan, KK., Sawchuk, RJ. Transient steady-state analysis: application in the determination of the relative formation and elimination clearances of two major carbamazepine metabolites in humans. Pharm Res, 10:1090-1092, 1993.
30. Keen, RE., Spain JD. Computer Simulation in Biology: A Basic Introduction. Wiley-Liss, Inc., New York, USA, pp55, 1993.
31. Gabrielsson, J., Weiner, D. Pharmacodynamic Concept, in Gabrielsson J: Weiner D (eds) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 2nd ed. Swedish Pharmaceutical Society, Swedish Pharmaceutical Press, Stockholm, Sweden, pp64, 186, 1997.
32. Tomson, T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol, 41:830-843, 1984.